Results 271 to 280 of about 53,476 (305)

Osteoprotegerin and Diabetic Macroangiopathy

Hormone and Metabolic Research, 2005
Osteoprotegerin (OPG) is a bone-related protein that is also present in the vasculature. Recent data suggest that it may play a special role in arterial disease among patients with diabetes. Diabetic macroangiopathy is characterized by a series of diffuse, non-atherosclerotic alterations that hypothetically increase the vulnerability of the vessel wall
Rasmussen, Lars Melholt, Ledet, Thomas
openaire   +3 more sources

Osteoprotegerin and kidney disease

Journal of Nephrology, 2014
Vascular calcification in chronic kidney disease (CKD) patients is associated to increased mortality. Osteoprotegerin (OPG) is a soluble tumor necrosis factor (TNF) superfamily receptor that inhibits the actions of the cytokines receptor activator of nuclear factor kappa-B ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL) by preventing ...
Alejandra, Montañez-Barragán, Isaias, Gómez-Barrera, Maria D, Sanchez-Niño, Alvaro C, Ucero, Liliana, González-Espinoza, Alberto, Ortiz   +5 more
openaire   +2 more sources

Osteoprotegerin inhibit osteoclast differentiation and bone resorption by enhancing autophagy via AMPK/mTOR/p70S6K signaling pathway in vitro

Journal of Cellular Biochemistry, 2018
Osteoclasts are highly differentiated terminal cells formed by fusion of hematopoietic stem cells. Previously, osteoprotegerin (OPG) inhibit osteoclast differentiation and bone resorption by blocking receptor activator of nuclear factor‐κB ligand (RANKL)
Xishuai Tong, Jianhong Gu, R. Song, Dong Wang, Z. Sun, Chen Sui, Chuang Zhang, Xuezhong Liu, Jianchun Bian, Zongping Liu   +9 more
semanticscholar   +1 more source

Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease

British Journal of Haematology, 2006
SummaryBone involvement in Gaucher disease causes disability and reduced quality of life; loss of function and pain are important indications for enzyme replacement therapy. The purpose of this study was to ascertain whether osteoprotegerin (OPG), which decreases osteoclast activity, is indicative of incipient bone involvement by comparing OPG serum ...
Itai, Magal, Ehud, Lebel, Gheona, Altarescu, Menachem, Itzchaki, Bernard, Rudensky, A Joseph, Foldes, Ari, Zimran, Deborah, Elstein   +7 more
openaire   +2 more sources

Osteoprotegerin and Osteopontin Serum Levels are Associated with Vascular Function and Inflammation in Coronary Artery Disease Patients.

Current Vascular Pharmacology, 2019
BACKGROUND Osteoprotegerin and osteopontin have recently emerged as key factors in both vascular remodelling and atherosclerosis progression. Interleukin-6 (IL-6) is an inflammatory cytokine with a key role in atherosclerosis.
K. Maniatis, G. Siasos, E. Oikonomou, M. Vavuranakis, M. Zaromytidou, K. Mourouzis, T. Paraskevopoulos, G. Charalambous, A. Papavassiliou, D. Tousoulis   +9 more
semanticscholar   +1 more source

Renal Transplantation Decreases Osteoprotegerin Levels

Transplantation Proceedings, 2006
Vascular calcifications are an important risk factor for cardiovascular mortality and morbidity in patients with chronic renal failure. Osteoprotegerin, a soluble decoy receptor for receptor activator NFkB ligand, has emerged as an independent predictive factor of atherosclerosis and vascular calcification in hemodialysis patients.
A S, Bargnoux, A M, Dupuy, V, Garrigue, S, Deleuze, J P, Cristol, G, Mourad   +5 more
openaire   +2 more sources

Osteoprotegerin and Diabetes-Associated Pathologies

Current Molecular Medicine, 2011
Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease.
A M, Blázquez-Medela, J M, López-Novoa, C, Martínez-Salgado   +2 more
openaire   +2 more sources

Osteoprotegerin: regulator, protector and marker

Orvosi Hetilap, 2008
A csontbiológia terén végzett vizsgálatok vezettek a tumornekrózis-faktorok családjába tartozó receptorok, így az osteoprotegerin és a receptor activator of nuclear factor κB (RANK) szerepének tisztázásához a csontátépülés folyamatának szabályozásában.
Taha, El Hadj Othmane, Gábor, Speer, Bertalan, Fekete, Tamás, Szabó, József, Egresits, Erzsébet, Fodor, István, Kiss, János, Nemcsik, András, Szabó, Zsófia, Németh, Miklós, Szathmári, András, Tislér   +11 more
openaire   +2 more sources

Role for osteoprotegerin in rheumatoid inflammation

Joint Bone Spine, 2004
Osteoprotegerin (OPG), a member of the TNF-receptor family expressed by osteoblasts, has documented effects on the regulation of bone metabolism. OPG inhibits bone resorption and binds with strong affinity to its ligand RANKL, thereby preventing RANKL from binding to its receptor RANK. This system is regulated by calcium-modifying hormones.
Nathalie, Saidenberg-Kermanac'h, Martine, Cohen-Solal, Natacha, Bessis, Marie-Christine, De Vernejoul, Marie-Christophe, Boissier   +4 more
openaire   +2 more sources

Osteoprotegerin Deficiency and Juvenile Paget's Disease

New England Journal of Medicine, 2002
Juvenile Paget's disease, an autosomal recessive osteopathy, is characterized by rapidly remodeling woven bone, osteopenia, fractures, and progressive skeletal deformity. The molecular basis is not known. Osteoprotegerin deficiency could explain juvenile Paget's disease because osteoprotegerin suppresses bone turnover by functioning as a decoy receptor
Michael P, Whyte, Sara E, Obrecht, Patrick M, Finnegan, Jonathan L, Jones, Michelle N, Podgornik, William H, McAlister, Steven, Mumm   +6 more
openaire   +2 more sources